Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines

Mohit, Elham; Hashemi, Atieh; Allahyari, Mojgan

doi:10.1586/1744666x.2014.916211

Cited by 38 publications

(21 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Constitutively activated in 20-30% of breast cancers, being responsible for dysregulated cell proliferation [12] and aggressive biological and clinical behavior [10]. These tumors are defined as ER-, PR-, and HER2+ [11].…”

Section: Her2-enrichedmentioning

confidence: 99%

Immunotherapy: A Challenge of Breast Cancer Treatment

García-Aranda

Redondo

2019

Cancers

140

View full text Add to dashboard Cite

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

show abstract

Section: Her2-enrichedmentioning

confidence: 99%

Immunotherapy: A Challenge of Breast Cancer Treatment

García-Aranda

Redondo

2019

Cancers

140

View full text Add to dashboard Cite

show abstract

“…These antigenic peptides can be identified through the analysis of specific antibody-inducing regions within larger proteins (epitopes), and are generally obtained through simple synthesis with high purity, in large scale, and at a lower cost (Gori et al, 2013;Purcell et al, 2007;Rosendahl Huber et al, 2014;Skwarczynski and Toth, 2011). Several peptide-based vaccine formulations have already reached the clinical development phase, as it is the case for some preventive HIV vaccines (Girard et al, 2006) as well as some therapeutic anticancer vaccines (Mohit et al, 2014;Ott et al, 2014).…”

Section: Peptidesmentioning

confidence: 99%

Nanoengineering of vaccines using natural polysaccharides

Cordeiro

Alonso

Fuente

2015

Biotechnology Advances

102

View full text Add to dashboard Cite

Currently, there are over 70 licensed vaccines, which prevent the pathogenesis of around 30 viruses and bacteria. Nevertheless, there are still important challenges in this area, which include the development of more active, non-invasive, and thermo-resistant vaccines. Important biotechnological advances have led to safer subunit antigens, such as proteins, peptides, and nucleic acids. However, their limited immunogenicity has demanded potent adjuvants that can strengthen the immune response. Particulate nanocarriers hold a high potential as adjuvants in vaccination. Due to their pathogen-like size and structure, they can enhance immune responses by mimicking the natural infection process. Additionally, they can be tailored for non-invasive mucosal administration (needle-free vaccination), and control the delivery of the associated antigens to a specific location and for prolonged times, opening room for single-dose vaccination. Moreover, they allow co-association of immunostimulatory molecules to improve the overall adjuvant capacity. The natural and ubiquitous character of polysaccharides, together with their intrinsic immunomodulating properties, their biocompatibility, and biodegradability, justify their interest in the engineering of nanovaccines. In this review, we aim to provide a state-of-the-art overview regarding the application of nanotechnology in vaccine delivery, with a focus on the most recent advances in the development and application of polysaccharide-based antigen nanocarriers.

show abstract

“…[4][5][6] Based on the tumor microenvironment and tumor-specific antigens, monoclonal antibodies (mAbs)-based targeted molecular therapy has attracted more and more attention. 7,8 Targeted therapy has become the focus in the field of tumor therapy because of its high efficacy and less number of side effects. 9 The mAbs therapies include cellular growth factor receptors 10 and cell surface antigens.…”

Section: Introductionmentioning

confidence: 99%

Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier

Zhang¹,

Zhu²,

Wu³

et al. 2018

IJN

View full text Add to dashboard Cite

Backgroundcis-Dichlorodiamineplatinum (CDDP) was one of the most common used drugs in clinic for cancer treatment. However, CDDP caused a variety of side effects. The abundant carboxyl groups on the surface of poly glutamic acid (PGA) could be modified with various kinds of targeted ligands. PGA delivery system loaded CDDP for cancer therapies possesses potential to overcome the side effects.Materials and methodsIn this study, we constructed a safe and efficient anticancer drug delivery system PGA–Asp–maleimide–cisplatin–peptide complex (PAMCP), which was loaded with CDDP and conjugated with the transferrin receptor (TFR)-targeting peptide through a maleimide functional linker. The size of PAMCP was identified by transmission electron microscopy (TEM) and dynamic light scattering (DLS). Fluorescence microscopy and flow cytometry methods were used to detect the cell targeting ability in vitro. The MTT assay was used to detect targeted toxicity in vitro. The in vivo acute toxicity was tested in Kun Ming (KM) mice. The tumor suppression activity and drug distribution was analyzed in nude mice bearing with HeLa tumor cells.ResultsThe nano-size was 110±28 nm detected with TEM and 89±18 nm detected with DLS, respectively. Fluorescence microscopy and flow cytometry methods indicated that PAMCP possessed excellent cell targeting ability in vitro. The MTT assay suggested that PAMCP was excellent for targeted toxicity. The acute in vivo toxicity study revealed that the body mass index and serum index in the PAMCP-treated group were superior to those in the CDDP-treated group (P<0.001), and no obvious differences were detected on comparing with the PBS- or PGA–Asp–maleimide–P8 (PAMP)-treated groups. PAMCP reduced the toxicity of CDDP, suppressed tumor cell growth, and achieved efficient anti-tumor effects in vivo. After PAMCP treatment, the toxicity of CDDP was reduced and tumor growth was more remarkably inhibited compared with the free CDDP treatment group (P<0.01). Much stronger (5–10 folds) fluorescence intensity in tumor tissue was detected compared with the irrelevant-peptide group for drug distribution analysis detected with the frozen section approach.ConclusionOur data highlighted that PAMCP reduced the side effects of CDDP and exhibited stronger anti-tumor effects. Therefore, PAMCP presented the potential to be a safe and effective anticancer pharmaceutical formulation for future clinical applications.

show abstract

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines

Cited by 38 publications

References 88 publications

Immunotherapy: A Challenge of Breast Cancer Treatment

Immunotherapy: A Challenge of Breast Cancer Treatment

Nanoengineering of vaccines using natural polysaccharides

Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier

Contact Info

Product

Resources

About

Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines

Cited by 38 publications

References 88 publications

Immunotherapy: A Challenge of Breast Cancer Treatment

Immunotherapy: A Challenge of Breast Cancer Treatment

Nanoengineering of vaccines using natural polysaccharides

Fabrication and evaluation of a &gamma;-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier

Contact Info

Product

Resources

About

Fabrication and evaluation of a γ-PGA-based self-assembly transferrin receptor-targeting anticancer drug carrier